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Introduction
RNA molecules can be divided into two major categories: 
protein-coding RNA and non-coding RNA (ncRNA). 
In human, around 98% of all transcriptional output is 
ncRNA (1). ncRNA can be further divided into two main 
subgroups based on their function: housekeeping ncRNA 
such as transfer RNA (tRNA), ribosomal RNA (rRNA), 
and regulatory ncRNA which includes both short and long 
ncRNA. It has become increasingly clear in recent years 
that regulatory ncRNA has profound biological function 
by regulating protein coding genes through a diverse array 
of molecular mechanisms. The best studied regulatory 
ncRNA is a class of tiny RNA molecules which have a size 
ranging from 20 to 30 nucleotides (nts) and highly depend 
on a family of conserved proteins known as Argonaute 
(Ago) for fuction. They include microRNA (miRNA), 
piwi-interacting RNA (piRNA) and small interfering 
RNA (siRNA). These small ncRNAs are mainly involved 
in an evolutionarily conserved gene silencing mechanism 
known as RNA interference (RNAi). Apart from their main 
function as silencers, we and other groups have recently 
reported that small RNA can also activate gene expression 
by targeting gene promoter sequences in a process termed 
RNA activation (RNAa) (2-4). These observations thus 
revealed a new class of small RNA molecules and a new 
layer of complexity of small RNA-mediated gene regulation 
(Table 1). It has become increasingly evident that various 
small RNA-guided gene regulations play important roles in 
normal physiological processes and in disease. It is also clear 
that these magnificent cellular mechanisms which were not 
known to us until recent years can be harnessed as powerful 
therapeutics for disease treatment. In this article, we review 
recent advances in the research of small RNA in urological 
and andrological diseases and focus on their potential 
application in the treatments of these diseases.
miRNA and its applications
miRNA and its biological functions
MicroRNA (miRNA) is a class of endogenous small RNA 
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(20-24 nt), which is transcribed from the genome and 
processed into its mature form by RNase III enzymes 
Drosha and Dicer via a multi-step process. Upon loaded 
by Ago proteins, miRNA binds to homologous sequences 
on the 3’untranslated regions (UTRs) of target messenger 
RNA (mRNA), resulting in translational repression and/or 
mRNA degradation (5). miRNA has also been shown to 
regulate gene expression by targeting gene promoters (6), 
5’-UTR (7), coding regions (8), pseudogenes (9) and 
competing endogenous RNA (ceRNA) (10). A recent report 
showed that miRNA could regulate gene translation in a 
“seed” sequence-independent manner (11). Various models 
of action for miRNA revealed so far imply that the miRNA 
has diverse functions in biology and disease.
The application of miRNA in urological cancers
Urological malignancies including cancer of the prostate, 
bladder and kidney are the leading causes of urological 
patient death. The molecular mechanisms underlying their 
development and progression remain poorly understood. 
Human miRNA genes are frequently located at fragile sites 
and genomic regions implicated in cancers (12), suggesting 
the involvement of miRNAs in this complicated biological 
processes (Table 2). With the improvement of RNA-
sequencing technology, hundreds of miRNAs have been 
identified and each miRNA are predicted to have hundreds 
of target genes.
According to their roles in cancer, miRNAs can be 
classified into oncogenic miRNAs (oncomiRs) and tumor 
suppressor miRNAs (tsmiRs). OncomiRs are generally 
upregulated in most tumor types and are able to promote 
malignant transformation and cancer progression. The 
well-known oncomiR is the miR-17-92 cluster consisting 
of several members including miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b-1 and miR-92a-1. The miR-17-92 
cluster is located at the 13q31 locus and amplified in 
many types of cancer (40). PTEN (phosphatase and tensin 
homologue) is one of the most frequently dysregulated 
tumor suppressors for several human urological cancers (41). 
Members of miR-17-92 cluster have been found to be able 
to inhibit PTEN expression via binding to its 3’UTR (13). 
mir-17-92 can also target and suppress the expression of 
BCL2L11(BIM) (13), TSP1 and CTGF genes (14). The 
miR-106b-25 cluster (miR-106b, miR-93 and miR-25), 
which shares high degree of homology with the miR-17-92 
cluster, can promote cell proliferation and resistance to 
apoptosis by inhibiting BIM, p21 (15), PTEN (16) and p53 (17). 
The miR-221/222 locus, located on chromosome X, 
is another widely recognized oncomiR cluster. The two 
miRNAs in this cluster are transcribed from the same 
promoter and share identical seed sequences. Functional 
studies showed these oncomiRs negatively module many 
tumor suppressor genes, including p27, p57 (18), DDIT4 (19), 
PTEN and TIMP3 (20). Although different types of human 
cancer may have different miRNA expression signatures, 
some oncomiRs are consistently associated with a high risk 
for malignancies, such as miR-21 (40). Overexpression of 
miR-21 could suppress apoptosis, induce cell proliferation 
and survival, and facilitate cell migration and invasion by 
suppressing such target genes as PDCD4 (21), PTEN (22), 
RHOB (23), RECK and TIMP3 (24).
Table 1 Classes of small RNA
Properties microRNA (miRNA)
Piwi-interacting  
RNA (piRNA)
Small interfering RNA 
(siRNA)
Small activating 
RNA (saRNA)
Size (nt) 20-24 24-30 21-23 21
Source Endogenous(ubiquitous) Endogenous(restricted largely to 
spermatocytes and spermatids)
Exogenous or  
endogenous
Exogenous or 
endogenous
Conservation Eukaryotes Vertebrates and invertebrates Eukaryotes Mammals
Strandedness Single-stranded Single-stranded Double-stranded Double-stranded
Biogenesis Dicer dependent Dicer independent Dicer dependent Dicer dependent
Ago dependence Ago subfamily Piwi subfamily Ago subfamily Ago subfamily
Target 3'-UTR, 5'-UTR, gene promoter, coding regions, 
pseudogenes and competing endogenous RNA
Transposon mRNA or gene promoter Gene promoter
Functions mRNA degradation,transcriptional silencing, 
posttranscriptional silencing, translation inhibition
Transposon silencing, 
transcriptional regulation,  
post-transcriptional regulation
mRNA degradation, 
transcriptional silencing, 
posttranscriptional silencing
Gene activation
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TsmiRs may inhibit cancers by suppressing oncogenes. 
Similar to protein-coding tumor suppressor genes, they 
are frequently deleted, mutated, or methylated in many 
human tumors (12,42). miR-15a and miR-16-1, located at 
human chromosome 13q14 and transcribed as a cluster, are 
the first identified tumor-suppressor miRNAs. Deletion 
or mutation of 13q14 locus was observed in many solid 
tumors and chronic lymphocytic leukemia (CLL) (12). 
Initially, miR-15a and miR-16-1 were found to be able to 
induce cell apoptosis by suppressing anti-apoptotic factor 
BCL2 in chronic lymphocytic leukemia (CLL) cells (25). 
Later studies showed that this cluster of miRNAs can also 
inhibit cell proliferation, induce apoptosis and suppress 
tumorigenicity by targeting multiple additional oncogenes 
in several signaling pathways, such as cell-cycle regulators 
(CCND1, CCND3, CCNE1 and CDK6) (26,27) and 
angiogenic factors and their receptors (VEGF, FGF2 and 
FGFR1) (28-30).
miR-143/145 is another important tsmiR cluster and 
is involved in suppressing the RAS and c-Myc signaling 
pathways (31,32). Systematic analysis of miRNA expression 
profile revealed that downregulation of miR-143 and 
miR-145 was associated with aggressive phenotype (43) in 
prostate cancer patients. BCL2/adenovirus E1B 19-kDa 
interacting protein 3 (BNIP3) is widely upregulated in 
human tumors and miR-145 negatively regulates BNIP3 
by targeting its 3’-UTR. Artificial restoration of miR-145 
reduced cell growth in prostate cancer cells (33). In bladder 
tumor tissues, miR-145 is one of the most underexpressed 
miRNAs (44) and is capable of inhibiting tumor cell growth 
and invasion by targeting FSCN1 in vitro (34). Interestingly, 
three key pluripotency genes (OCT4, SOX2 and KLF4) 
essential for stem cell fate decision were demonstrated to be 
direct targets of miR-145 in both human embryonic stem 
cells (35) and cancer cells (36).
Beyond their role in cell growth control, miRNAs 
can also affect tumorigenesis and cancer progression via 
additional signaling pathways. For instance, miR-200 
family and miR-205 which are frequently downregulated 
in invasive bladder and prostate cancer act as Epithelial-
mesenchymal transition (EMT) repressors by targeting 
ZEB1 and ZEB2 (37). Moreover, miRNAs have been 
implicated in the regulation of epigenetics. Loss of miR-101 
and miR-449a in prostate cancer cells led to overexpression 
of histone methyltransferase EZH2 (38) and histone 
deacetylase HDAC-1 (39), respectively.
Several studies have revealed that tumor suppressor 
factors (i.e. tumor suppressor genes, tsmiRs) and oncogenic 
factors (i.e. oncogenes, oncomiRs) are exquisitely regulated 
in organisms. On one hand, miRNAs are critical downstream 
effectors of classic oncogene/tumor suppressor networks. 
For examples, the transcription of miR-17-92 cluster 
and miR-34 family is directly activated by c-Myc and 
p53, respectively (45,46). And p53 can also module the 
biogenesis of miR-16-1, miR-143 and miR-145 (32,47). On 
the other hand, miR-145 suppresses c-Myc via targeting its 
3’UTR (32), while mir-25 (a homologous miRNA of the 
miR-17-92 cluster) inhibits p53 by its 3’UTR (17).
Supplementation of tsmiRs or inhibition of oncomiRs 
by antagomirs could be a new class of targeted molecular 
therapy. For instance, miR-15a and miR-16 are significantly 
decreased in cancer cells of advanced prostate tumors. 
Delivery of antagomirs specific for miR-15a and miR-16 
to normal mouse prostate caused hyperplasia, but 
reconstitution of miR-15a and miR-16-1 expression led to 
growth arrest, apoptosis and regression of prostate tumor 
xenografts (27). Another independent study also reported that 
systemic delivery of synthetic miR-16 via tail vein injection 
significantly inhibited the growth of metastatic prostate tumors 
in a prostate cancer xenograft model in nude mice (48).
Table 2 Involvement of miRNA in urological cancers
Role microRNA Validated targets References
OncomiRs
miR-17-92 PTEN, BIM, TSP1 and CTGF (13,14)
miR-106b-25 BIM, p21, PTEN and p53 (15-17)
miR-221/222 p27, p57, DDIT4, PTEN and TIMP3 (18-20)
miR-21 PDCD4, PTEN, RHOB, RECK and TIMP3 (21-24)
TsmiRs
miR-15a/miR-16-1 BCL2, CCND1, CCND3, CCNE1, CDK6, VEGF, FGF2 and FGFR1 (25-30)
miR-143/145 RAS, c-Myc, BNIP3, FSCN1, OCT4, SOX2 and KLF4 (31-36)
miR-200 family and miR-205 ZEB1 and ZEB2 (37)
miR-101 EZH2 (38)
miR-449a HDAC-1 (39)
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The application of miRNA in andrology
Although miRNAs have been intensively studied in cancer, 
their physiological roles in andrology are much less 
clear. Some recent works suggest that miRNAs may have 
regulatory role in testicular and epididymal development 
and spermatogenesis. A systematic cDNA array and miRNA 
array analysis showed that neonatal epididymis expressed 
more miRNAs than that of young adults and aged men. 
Some of the miRNAs expressing high in young adults 
include miR-143, miR-7a, miR-21, miR-23a, miR-24, 
miR-27a/b and miR-29a (49). In young adults, male infertility 
may be associated with dysexpression of certain miRNAs. 
Compared with fertile males, miR-34c-5p, miR-122, 
miR-146b-5p, miR-181a, miR-374b, miR-509-5p and 
miR-513a-5p are dramatically decreased in azoospermia 
patients, but increased in asthenozoospermia (50). Another 
work performed in non-obstructive azoospermia patients 
identif ied 19 differential ly up-regulated and 154 
downregulated miRNAs. Among the downregulated ones are 
some testicular miRNAs (miR-181a, miR-29c, and miR-34b*) 
and several members of the miR-17-92 cluster (51). 
It is interesting that miR-17-92 cluster is highly expressed 
in primordial germ cells and spermatogonia during 
development of mouse germ cells (52). It is known that 
single-nucleotide polymorphisms (SNPs) inside miRNA 
target sites (miR-TS-SNPs) may influence miRNA 
biogenesis and susceptibility to tumorigenesis (53). 
Recently, these SNPs were found to be implicated in 
male infertility. Some fertility related genes contain miR-
TS-SNPs, and the most polymorphic were identified in 
the 3’UTR of KITL, ACTB, ACE, CAMK4, ESR1 and 
MTHFR (54). Ogorevc et al. also analyzed the relationships 
between selected infertile candidate genes and dysexpressed 
miRNAs in non-obstructive azoospermic patients and found 
3 upregulated and 10 downregulated miRNA contained 
miR-TS-SNPs (54). These works suggested that miRNA 
expression profiles may serve as noninvasive molecular 
markers for male infertility diagnosis.
piRNA and its applications
piRNA and its biological functions
Piwi-interacting RNA (piRNA) is a class of endogenous 
single-stranded small RNAs (24-30 nt) found in both 
vertebrates and invertebrates. Distinct from miRNAs, 
piRNAs are transcribed from specific genomic regions 
containing repetitive elements, such as transposable 
elements, and processed into its mature form by a Dicer-
independent pathway. At the assistance of Piwi and Aub 
proteins, piRNA is implicated in transposon silencing at 
both the transcriptional and post-transcriptional levels (55). 
Opposite to the well known piRNA-mediated silencing, 
piRNA is also able to function as an epigenetic activator. 
3R-TAS1 piRNA, a piRNA transcribed from a region of 
the telomere-associated sequence (TAS) on the right arm 
of chromosome 3 (3R-TAS) in Drosophila, promotes the 
euchromatic character of 3R-TAS heterochromatin and its 
transcriptional activity (56).
The application of piRNA in andrology and urology
Different from miRNA’s ubiquitous expression in different 
tissues and organs, piRNA is specifically present in 
spermatocytes and spermatids during spermatogenesis (57). 
Thus, it is believed that piRNA plays an essential role 
in germline development. In mice, PIWI-like proteins 
subfamily consists of MIWI, MIWI2, and MILI, and 
deficiencies of these members cause aberrant male germ cell 
development. MIWI-deficient mice display spermatogenic 
arrest at the beginning of the round spermatid stage (58). 
Spermatogenesis in the MILI-null mice is blocked at the 
early prophase of the first meiosis (59). MIWI2 -deficient 
mice display a defect in early prophase of meiosis I and a 
marked and progressive loss of germ cells with age (60). 
Despite considerable knowledge has been gained about the 
function of piRNA in Drosophila and mice, their function 
in human is obscure. Recently, nine SNPs of four human 
Piwi genes (PIWIL1/HIWI, PIWIL2/HILI, PIWIL3/
HIWI3 and PIWIL4/HIWI2) were identified in patients 
with idiopathic azoospermia or oligozoospermia. Among 
them, an SNP in the 3’UTR region of HIWI2 and a non-
synonymous SNP in HIWI3 were significantly associated 
with an altered risk of oligozoospermia (61). Furthermore, 
Hiwi (human Piwi ortholog) has been found to be 
aberrantly expressed in a variety of human cancers (62) and 
its overexpression correlates with poor clinical prognosis of 
soft-tissue sarcoma patients (63), while there has been no 
report of its association with urological cancers.
siRNA and its applications
siRNA and its biological functions
Small interfering RNA (siRNA) is a class of 21- to 23-nt 
double-stranded RNAs (dsRNAs) endogenously generated 
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or artificially designed and is the trigger of the well-known 
RNA interference (RNAi) mechanism. RNAi can be induced 
by exogenously introduced dsRNAs (64), or endogenous 
dsRNAs (65). In addition, plasmid-expressed short hairpin 
RNA (shRNA) can also be used to silence gene expression 
via RNAi pathway (66). It is well known that many human 
diseases are caused by abnormal overproduction of specific 
gene products, such as oncogenes. Therefore, siRNA 
or shRNA targeting disease-causing gene is promising 
therapeutic for many diseases (Table 3).
The application of siRNA in urological cancers
Apoptosis (programmed cell death) is a crucial biological 
process in cancer initiation and progression. Cancer cells 
overexpress many anti-apoptotic genes (i.e. survivin, BCL2, 
etc) or underexpress pro-apoptotic genes (i.e. caspase 
family) to maintain aggressive cell proliferation. Resisting 
cell death caused by dysregulation of apoptosis related genes 
is one of the fundamental hallmarks of cancer and is a major 
target for cancer therapy (84). Abnormal upregulation of 
survivin may inhibit caspase activity and enable cancer cells 
to escape programmed cell death and promote resistance 
to radiation and chemotherapy. Vector-based siRNA 
expression effectively suppressed survivin expression and led 
to decreased tumor formation in nude mice bearing prostate 
cancer xenografts and enhanced chemosensitivity (67). 
Knockdown of survivin Null by siRNA in bladder cancer 
cells also suppressed their growth in vitro and in vivo (72). 
Similarly, BCL2 downregulation by siRNA enhanced 
mitomycin C induced apoptotic cell death in bladder cancer 
cell lines (73). Stat3 belongs to the STAT transcription 
factor family and functions as an oncogenic transcription 
factor by promoting proliferation, anti-apoptosis and cell 
cycle progression. RNAi of Stat3 led to downregulation 
of its downstream genes including BCL2, cyclin D1 and 
c-Myc in prostate cancer cell lines and in tumors implanted 
in nude mice (68). EphB4 is a receptor protein tyrosine 
kinase aberrantly expressed in bladder cancer cell lines and 
tumor specimens. EphB4 knockdown in vitro using siRNA 
suppressed cell viability by inducing apoptosis via activation 
of caspase-8 pathway and by inhibiting anti-apoptotic 
factor, Bcl-xl. EphB4 siRNA delivered into tumors was able 
to alleviate xenograft tumor burden in vivo (74).
Overactivated mitosis is another essential cause for 
the aberrant proliferation signaling in cancer cells. Polo-
like kinase-1 (PLK1) is a critical regulator of mitotic 
progression. Elevated PLK1 expression in patients with 
bladder cancer and renal cell carcinoma is frequently 
associated with poor prognosis. siRNA targeting PLK1 
could disrupt cell mitosis and cell cycle progression and thus 
reduced cell proliferation in bladder cancer and renal cancer 
cells (75,77). In an orthotopic bladder cancer mouse model, 
PLK1 siRNA delivery successfully prevented bladder cancer 
Table 3 The application of siRNA in urology and andrology
Disease Target gene Trigger RNA Applications References
Prostate cancer Survivin shRNA In vitro, in vivo (xenograft) (67)
Stat3 shRNA In vitro, in vivo (xenograft) (68)
FOXO3/Foxo3 siRNA In vitro (69)
Integrin αv siRNA In vitro, in vivo (xenograft) (70)
PLK1 and BCL2 aptamer-siRNA chimeras In vitro, in vivo (xenograft) (71)
Bladder cancer Survivin siRNA In vitro, in vivo (xenograft) (72)
BCL2 siRNA In vitro (73)
EphB4 siRNA In vitro, in vivo (xenograft) (74)
PLK1 siRNA In vitro, in vivo (75)
Renal cancer SOCS3 siRNA In vitro, in vivo (xenograft) (76)
PLK1 siRNA In vitro (77)
Survivin siRNA In vitro (78)
Erectile dysfunction PDE5/ PDE5 shRNA/siRNA In vitro, in vivo (79-81)
PIN shRNA/siRNA In vitro, in vivo (82)
CX43 shRNA In vitro (83)
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cell growth (77).
Evading immune destruction is also one of the hallmarks 
of cancer development and progression (84). Interferons 
are essential parts of the primary immune system by 
effectively triggering protective response, such as activating 
natural killer cells and macrophages, and facilitating 
antigen presentation to T lymphocytes. SOCS3 have been 
identified as an inhibitor of the IFN-mediated JAK⁄STAT 
signaling pathways. Suppression of SOCS3 by siRNA 
promoted IFN-α-induced cell death in renal cell carcinoma 
xenografts in nude mice (76). Dendritic cells (DCs) are 
the most potent antigen-presenting cells, while DCs can 
also induce tolerance, rather than immune activation. In 
tumors from human prostate cancer patients and transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mice, 
tumor-associated dendritic cells (TADCs) possess increased 
FOXO3/Foxo3 expression resulting in suppressed T cell 
function. Silencing FOXO3/Foxo3 with siRNAs could 
block its inhibitory effect on T cells, promote expression of 
costimulatory molecules and proinflammatory cytokines, 
and diminish expression of tolerogenic factors (69).
High pathological grades of malignancy is usually 
reflected in local invasion and distant metastasis. Integrins 
are one of major cell adhesion components, which can 
determine cells fate by controlling cell replication, migration 
and differentiation, especially in cancer metastasis (41). 
siRNA targeting Integrin αv, an ECM receptor gene, 
inhibited growth of human prostate cancer in a bone 
xenograft imaging model (70).
Clinical application of siRNA for cancer therapy 
highly depends on the efficiency and cell-type specificity 
of siRNA delivery. Sato et al. reported that Topotecan, a 
topoisomerase I inhibitor able to enhance survivin siRNA, 
caused renal cancer cell growth suppression by increasing 
cellular uptake of the siRNA (78). Furthermore, siRNAs 
targeting PLK1 and BCL2 were linked to an aptamer 
which specifically recognized prostate specific membrane 
antigen (PSMA) could inhibite tumor growth and mediate 
tumor regression in a xenograft prostate cancer model, 
by selectively binding to prostate cancer cells and tumor 
vascular endothelium (71).
The application of siRNA in andrology
Erectile dysfunction (ED) is a common andrological 
disorder, especially in aged men or men with diabetes. 
During physiological process of erection, nitric oxide 
(NO) release triggers the accumulation of cyclic guanosine 
monophosphate (cGMP) in cavernous smooth muscle cells 
(CSMCs), which subsequently induces increased blood 
flows into the corpus cavernosum and finally stimulates an 
erection by loosing smooth muscle cells. Dysregulation 
of NO synthesis and cGMP accumulation may result 
in erectile dysfunction (ED). Phosphodiesterase type 5 
(PDE5) can catalyze the degradation of cGMP and suppress 
erectile function. Lin et al. reported that a lentiviral vector-
based siRNA expression caused the knockdown of PDE5 
and prolonged accumulation of cGMP in cultured rat 
CSMCs. Injection of the lentiviral vector into rat penis 
significantly enhanced erectile function (79). Synthetic 
siRNA or shRNA vector-mediated PDE5 silencing also led 
to enhanced cGMP in cultured human CSMCs (80,81). 
siRNA or shRNA-mediated knockdown of PIN (protein 
inhibitor of NOS), a key repressor of nNOS (neuronal 
nitric oxide synthase), elevated cGMP concentration in 
vitro and improved erectile dysfunction in aged rats (82). 
Additionally, aberrant upregulation of CX43 (connexin43) 
is usually associated with ED. CX43 siRNA could decrease 
GJIC (gap junction intercellular communication) in 
cultured human CSMCs (83). Taken together, siRNA may 
have a therapeutic application in ED treatment; however, 
delivery of siRNA into corpus cavernosum tissue may be 
challenging and awaits further development.
saRNA and its applications
SaRNA and its biological functions
RNA activation (RNAa) is a newly discovered mechanism 
of gene regulation triggered also by small dsRNA that 
targets gene promoter regions instead of coding sequences. 
These promoter-targeted dsRNAs that can activate gene 
expression are referred to as small activating RNA (saRNA) 
(2,4). saRNA has been shown to activate the expression of 
endogenous genes (2-4), presenting a novel and natural 
tool of overexpressing functionally important genes for 
disease treatment. Vector-based systems offer robust gene 
overexpression and are being tested as a promising gene 
therapy strategy for the treatment of a variety of diseases. 
However, serious concerns of insertional mutagenesis in 
clinical settings are associated with the use of viral vectors. 
As an alternative, RNAa may offer a safer approach for 
gene overexpression and disease treatment. Several recent 
studies have shown that saRNA-mediated gene activation 
can suppress cancer cell growth by upregulating tumor 
suppressor genes and improve smooth muscle function by 
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activating VEGF gene (Table 4).
The application of saRNA in urological cancers
It is well known that tumorigenesis and cancer progression 
correlates with inactivation of tumor suppressor genes. 
p21 is a cyclin-dependent kinase inhibitor that functions 
as a key mediator of cell-cycle arrest and down-regulation 
of p21 is frequently observed in different types of cancers. 
Several studies showed that restoration of p21 expression by 
saRNA can inhibit cell proliferation, cell cycle progression, 
and induce apoptosis in prostate, bladder and renal 
cancer cells (2,89,90,92). It is believed that EMT plays an 
important role in the initiation and progression of cancer. 
E-cadherin, a key mediator in EMT signaling, can serves as 
a potent inhibitor of cancer cell growth and invasion (84). 
Overexpression of E-cadherin by saRNAs led to inhibited 
cell proliferation and suppression of migration and invasion 
of prostate and bladder cancer cells (2,85,91). NKX3-1 
is a prostate specific tumor suppressor gene and could be 
activated by its promoter-targeted saRNA (87).
Recently, our group has utilized RNAa as a laboratory tool 
to investigate the function of KLF4, a member of the Krüppel-
like family of transcription factors, in prostate cancer cells in 
which KLF4 expression is significantly downregulated (86). In 
vitro studies indicated that saRNA-mediated overexpression of 
KLF4 inhibited prostate cancer cell proliferation and survival, 
and altered the expression of its downstream cell-cycle–related 
genes including p21, p27, p57 and CCNB1. Reactivation of 
KLF4 by saRNA also suppressed migration and invasion of 
prostate cancer cells (86).
It is largely recognized that miRNA functions as a 
silencer of gene expression. Our recent work indicates 
that miRNAs may also positively-regulate gene expression 
by targeting promoter sequences and thus act as saRNA. 
In human prostate cancer PC-3 cells, introduction of 
pre-miR-373/miR-373 could activate E-cadherin and 
CSDC2 (cold-shock domain-containing protein C2) (6). 
Cyclin B1 is an essential protein that drives cell cycle entry 
into mitosis and is a cancer antigen highly expressed in a 
majority of human cancer (88). In mouse prostate cells (i.e. 
TRAMP C1), we recently identified three miRNAs (miR-
744, miR-1186 and miR-466d-3p) that target the cyclin 
B1 promoter to induce Ccnb1 expression in a physiological 
context. Short-term overexpression of miR-744 and miR-
1186 resulted in enhanced cell proliferation, while long-
term expression caused chromosomal instability and tumor 
suppression in vivo (88). This study thus provided the first 
example that RNAa mechanism functions as an endogenous 
cellular process and is exploited by cancer cells to gain a 
growth advantage.
The application of saRNA in andrology
Vascular endothelial growth factor (VEGF) is a well-known 
cytokine with strong angiogenic properties and can also 
stimulate cell proliferation, delay senescence, suppress 
apoptosis and promote nerve regeneration. Vector-based 
overexpression of VEGF has been shown to improve 
erectile function (94). Our group identified a saRNA 
with the capacity to activate VEGF in human (2) and 
nonhuman primates cells (87). Very recently, this saRNA 
was demonstrated to induce endogenous VEGF expression 
in primary human corpus cavernosum smooth muscle cells 
(CCSMCs) in vitro (93). Delivering an saRNA targeting 
mouse VEGF by lentivirus into mice resulted in improved 
vascularity and blood flow in an ischemic mouse hindlimb 
model (95). These studies imply that saRNA-meditated 
Table 4 The application of saRNA in urology and andrology
Disease Species Gene Trigger RNA Applications References
Prostate cancer Human p21 saRNA In vitro, in vivo (xenograft) (2)
Human E-cadherin saRNA and miRNA In vitro (2,6,85)
Human KLF4 saRNA In vitro (86)
Human NKX3.1 saRNA In vitro, in vivo (xenograft) (87)
Mouse Ccnb1 saRNA and miRNA In vitro, in vivo (xenograft) (87,88)
Bladder cancer Human p21 saRNA In vitro, in vivo (xenograft) (89,90)
Human E-cadherin saRNA In vitro (91)
Renal cancer Human p21 saRNA In vitro (92)
ED Human VEGF saRNA In vitro (93)
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VEGF upregulation may present a new avenue for treating 
ED and other vascular disorders.
Prospectives
Despite tons of efforts have been made to develop small 
RNA-based therapeutics, the scientific and pharmaceutical 
communities are still facing significant hurdles in bringing 
small RNA drugs (ribodrugs) to the clinic. Among them, 
efficient delivery to target tissue and cells is the greatest 
challenge (96). Recently, promising results have been 
reported from the first-ever phase I clinical trial of siRNA 
delivered by nanoparticles for treating melanoma (97). 
Many other clinical trials of siRNA-based drugs for a 
large array of diseases are ongoing with some having 
advanced into phase II. With the rapid progression in the 
development of small RNA delivery technology, we believe 
that in the future not far away from now ribodrugs will be 
an indispensable weapon in the arsenal of urologists and 
andrologists for fighting against a variety of diseases.
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